Sintilimab

Generic Name
Sintilimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
2072873-06-2
Unique Ingredient Identifier
8FU7FQ8UPK
Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients

First Posted Date
2020-09-14
Last Posted Date
2023-02-15
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
50
Registration Number
NCT04548440
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer

First Posted Date
2020-09-01
Last Posted Date
2021-05-11
Lead Sponsor
Fudan University
Target Recruit Count
60
Registration Number
NCT04535024
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR -, ALK -) After Failure of Platinum-based Chemotherapy: A Randomized,Open Labled, Phase II Clinical Study

First Posted Date
2020-08-14
Last Posted Date
2020-08-14
Lead Sponsor
Shanghai Cancer Hospital, China
Target Recruit Count
70
Registration Number
NCT04513301
Locations
🇨🇳

Fudan University shanghai cancer center, Shanghai, Shanghai, China

Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer

Phase 2
Conditions
Oligometastasis
Lung Neoplasms
Interventions
Drug: Sintilimab
First Posted Date
2020-07-24
Last Posted Date
2020-07-24
Lead Sponsor
Tianjin Medical University Second Hospital
Target Recruit Count
44
Registration Number
NCT04486287

Study on Sintilimab in Stage IV High Risk Neuroblastoma

First Posted Date
2020-06-02
Last Posted Date
2020-08-11
Lead Sponsor
Shanghai Children's Medical Center
Target Recruit Count
10
Registration Number
NCT04412408
Locations
🇨🇳

Shanghai Children's Medical Center Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China

Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant Tumors

Phase 1
Conditions
Pediatric Cancer
Interventions
Drug: Sintilimab
First Posted Date
2020-05-26
Last Posted Date
2020-09-03
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
18
Registration Number
NCT04400851
Locations
🇨🇳

Yizhuo Zhang, Guangzhou, China

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Phase 2
Withdrawn
Conditions
ICC
Metastatic Cancer
Interventions
Drug: Folfirinox
Drug: Sintilimab
First Posted Date
2020-05-22
Last Posted Date
2021-02-04
Lead Sponsor
Sun Yat-sen University
Registration Number
NCT04398927
Locations
🇨🇳

Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

First Posted Date
2020-04-22
Last Posted Date
2020-07-14
Lead Sponsor
Fudan University
Target Recruit Count
45
Registration Number
NCT04356872
Locations
🇨🇳

Fudan University, Cancer Hospital, Shanghai, Shanghai, China

Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer

First Posted Date
2020-03-11
Last Posted Date
2023-02-01
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
195
Registration Number
NCT04304209
Locations
🇨🇳

Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study

Phase 2
Recruiting
Conditions
Cutaneous T-cell Lymphoma
Interventions
Drug: Sintilimab
Drug: Chidamide
First Posted Date
2020-03-05
Last Posted Date
2020-03-05
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
52
Registration Number
NCT04296786
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy